mutLBSgeneDB

mutLBSgeneDB
mutated Ligand Binding Site gene DataBase

Home

Download

 Statistics

Help

About Us

Bioinformatics and Systems Medicine Laboratory Bioinformatics and Systems Medicine Laboratory

Gene Summary

Ligand Binding Site Mutation Information

Protein Structure Related Information

Gene Expression and Gene-Gene Network

Phenotype Information

Pharmacological Information

Conservation Information for LBS

Gene summary for ARRDC3
Gene summary
Basic gene Info.Gene symbolARRDC3
Gene namearrestin domain containing 3
SynonymsTLIMP
CytomapUCSC genome browser: 5q14.3
Type of geneprotein-coding
RefGenesNM_020801.2,
DescriptionTBP-2-like inducible membrane proteinalpha-arrestin 3arrestin domain-containing protein 3thioredoxin-binding protein-2-like inducible membrane
Modification date20141207
dbXrefs MIM : 612464
HGNC : HGNC
Ensembl : ENSG00000113369
HPRD : 09810
Vega : OTTHUMG00000162616
ProteinUniProt: Q96B67
go to UniProt's Cross Reference DB Table
ExpressionCleanEX: HS_ARRDC3
BioGPS: 57561
PathwayNCI Pathway Interaction Database: ARRDC3
KEGG: ARRDC3
REACTOME: ARRDC3
Pathway Commons: ARRDC3
ContextiHOP: ARRDC3
ligand binding site mutation search in PubMed: ARRDC3
UCL Cancer Institute: ARRDC3
Assigned class in mutLBSgeneDBC: This gene just belongs to mutLBSgenes.

Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez
GO IDGO TermPubMed ID


Top
Ligand binding site mutations for ARRDC3

Cancer type specific mutLBS sorted by frequency
LBSAAchange of nsSNVCancer type# samples
R52R52GCOAD1
K45S46FCOAD1
K45S46YCOAD1
H50I49SCOAD1
R52R52SCOAD1
R135R135CGBM1
R135,W137Y136CSTAD1
cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma.


Top
Protein structure related information for ARRDC3
Relative protein structure stability change (ΔΔE) using Mupro 1.1
Mupro score denotes assessment of the effect of mutations on thermodynamic stability.
  (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability)
: nsSNV at non-LBS: nsSNV at LBS

nsSNVs sorted by the relative stability change of protein structure by each mutation
Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene.
LBSAAchange of nsSNVRelative stability change
H50I49S-1.6957029
R135R135C-1.2946094
R52R52G-0.97268466
R52R52S-0.7811962
W137Y136C-0.77338297
R135Y136C-0.77338297
K45S46Y-0.64674606
K45S46F-0.60759025
(MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132)

Structure image for ARRDC3 from PDB

Top
Differential gene expression and gene-gene network for ARRDC3
Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types

Differential co-expressed gene network based on protein-protein interaction data (CePIN)
* Left PPI network was created from samples with mutations in the LBS of ARRDC3 and the right PPI network was created from samples without mutations in the LBS of ARRDC3. Only genes with p-value < 0.05 are shown.
Red circle: input gene. Orange circle: LBSgene. Blue circle: other gene.


Top

Top
Phenotype information for ARRDC3
Gene level disease information (DisGeNet)
Disease IDDisease name# PubMedAssociation type
umls:C1458155Breast Neoplasms1Biomarker

Mutation level pathogenic information (ClinVar annotation)
Allele IDAA changeClinical significanceOriginPhenotype IDs

Top
Pharmacological information for ARRDC3
Drug information targeting mutLBSgene (Approved drugs only)
Drug statusDrugBank IDNameTypeDrug structure

Gene-centered ligand-gene interaction network

Ligands binding to mutated ligand binding site of ARRDC3 go to BioLip
Ligand IDLigand short nameLigand long namePDB IDPDB namemutLBS
PO4PHOSPHATE ION4r7xAH50
PO4PHOSPHATE ION4r7xBH50
PO4PHOSPHATE ION4r7xAK45
PO4PHOSPHATE ION4r7xAR135 W137
PO4PHOSPHATE ION4r7xBR135 W137
PO4PHOSPHATE ION4r7xBR52


Top
Conservation information for LBS of ARRDC3
Multiple alignments for Q96B67 in multiple species
LBSAA sequence# speciesSpecies
E141YWVKAELHRPW4Homo sapiens, Bos taurus, Rattus norvegicus, Mus musculus
H103SEEGFHTIHSG2Homo sapiens, Mus musculus
H103SEEGFNTIHSG1Bos taurus
H103CEEGFSTIHSG1Rattus norvegicus
H110IHSGRHEYAFS4Homo sapiens, Bos taurus, Rattus norvegicus, Mus musculus
H143VKAELHRPWLL4Homo sapiens, Bos taurus, Rattus norvegicus, Mus musculus
H50KSLKIHARGHA4Homo sapiens, Bos taurus, Rattus norvegicus, Mus musculus
H54IHARGHAKVRW4Homo sapiens, Bos taurus, Rattus norvegicus, Mus musculus
K139VRYWVKAELHR4Homo sapiens, Bos taurus, Rattus norvegicus, Mus musculus
K151WLLPVKLKKEF4Homo sapiens, Bos taurus, Rattus norvegicus, Mus musculus
K153LPVKLKKEFTV4Homo sapiens, Bos taurus, Rattus norvegicus, Mus musculus
K45GEIRVKSLKIH4Homo sapiens, Bos taurus, Rattus norvegicus, Mus musculus
K56ARGHAKVRWTE4Homo sapiens, Bos taurus, Rattus norvegicus, Mus musculus
P149RPWLLPVKLKK4Homo sapiens, Bos taurus, Rattus norvegicus, Mus musculus
R135RHGSVRYWVKA4Homo sapiens, Bos taurus, Rattus norvegicus, Mus musculus
R52LKIHARGHAKV4Homo sapiens, Bos taurus, Rattus norvegicus, Mus musculus
R58GHAKVRWTESR4Homo sapiens, Bos taurus, Rattus norvegicus, Mus musculus
W137GSVRYWVKAEL4Homo sapiens, Bos taurus, Rattus norvegicus, Mus musculus
Y112SGRHEYAFSFE4Homo sapiens, Bos taurus, Rattus norvegicus, Mus musculus


Copyright © 2016-Present - The University of Texas Health Science Center at Houston
Site Policies | State of Texas